Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).   We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor   Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: ⁠https://x.com/oncbrothers⁠  ⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠  Website: ⁠https://oncbrothers.com/⁠    Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers